Strategic Relationships

BioAtla’s strategy is to advance a large portfolio of CABs in a variety of formats that can be used individually and in combinations to best treat particular cancer indications. We are very selective in our partnerships and ideally will take our drug candidates through clinical proof of concept before partnering.


Himalaya Therapeutics is a clinical stage, therapeutic company focused on developing innovative, differentiated therapies in greater china and worldwide with the goal of delivering safer, more potent cancer therapies to patients timely and cost effectively. Himalaya's strategic approach is to manage and coordinate drug development from lead to IND to market through its internal capabilities as well as through leading contract providers and strategic partners.

Himalaya has the exclusive license from BioAtla to develop and commercialize several specific CAB candidates for the Greater China market of the PRC, Hong Kong, Macau and Taiwan, including two Phase 1/2 clinical stage assets, as well as worldwide rights to two additional preclinical drug candidates.